Banco Santander S.A. Invests $244,000 in Kenvue Inc. (NYSE:KVUE)

Banco Santander S.A. purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 11,450 shares of the company’s stock, valued at approximately $244,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Alerus Financial NA increased its position in Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC grew its stake in shares of Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after purchasing an additional 500 shares during the last quarter. Principle Wealth Partners LLC increased its holdings in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after purchasing an additional 500 shares in the last quarter. White Pine Capital LLC raised its position in Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after purchasing an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Kenvue by 29.0% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after buying an additional 568 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 2.0 %

KVUE opened at $23.90 on Tuesday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The firm has a market cap of $45.67 billion, a PE ratio of 45.09, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm’s fifty day moving average is $21.69 and its two-hundred day moving average is $22.35.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.43%. Kenvue’s dividend payout ratio is presently 154.72%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, Canaccord Genuity Group increased their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.